Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer.
O'Dwyer, P J
Greco, F A
Köhne, C H
Di Constanzo, F
Pensel, R A
Aykan, N F
Seymour, M T
MeSHAntineoplastic Combined Chemotherapy Protocols
Proportional Hazards Models
Randomized Controlled Trials as Topic
MetadataShow full item record
CitationAlpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer. 2001, 84 (5):611-20 Br. J. Cancer
JournalBritish journal of cancer
AbstractTwo meta-analyses were conducted to quantify the benefit of combining alpha-IFN to 5FU in advanced colorectal cancer in terms of tumour response and survival. Analyses were based on a total of 3254 individual patient data provided by principal investigators of each trial. The meta-analysis of 5FU +/- LV vs. 5FU +/- LV + alpha-IFN combined 12 trials and 1766 patients. The meta-analysis failed to show any statistically significant difference between the two treatment groups in terms of tumour response or survival. Overall tumour response rates were 25% for patients receiving no alpha-IFN vs. 24% for patients receiving alpha-IFN (relative risk, RR = 1.02), and median survivals were 11.4 months for patients receiving no alpha-IFN vs. 11.5 months for patients receiving alpha-IFN (hazard ratio, HR = 0.95). The meta-analysis of 5FU + LV vs. 5FU + alpha-IFN combined 7 trials, and 1488 patients. This meta-analysis showed an advantage for 5FU + LV over 5FU + alpha-IFN which was statistically significant in terms of tumour response (23% vs. 18%; RR = 1.26;P = 0.042), and of a borderline significance for overall survival (HR = 1.11;P = 0.066). Metastases confined to the liver and primary rectal tumours were independent favourable prognostic factors for tumour response, whereas good performance status, metastases confined to the liver or confined to the lung, and primary tumour in the rectum were independent favourable prognostic factors for survival. We conclude that alpha-IFN does not increase the efficacy of 5FU or of 5FU + LV, and that 5FU + alpha-IFN is significantly inferior to 5FU + LV, for patients with advanced colorectal cancer.
- Clinical impact of adjuvant chemotherapy on patients with stage III colorectal cancer: l-LV/5FU chemotherapy as a modified RPMI regimen is an independent prognostic factor for survival.
- Authors: Hotta T, Takifuji K, Arii K, Yokoyama S, Matsuda K, Higashiguchi T, Tominaga T, Oku Y, Yamaue H
- Issue date: 2006 Mar-Apr
- Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.
- Authors: Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, O'Connell M, Sargent P, Piedbois P, Meta-Analysis Group in Cancer.
- Issue date: 2004 Sep 15
- Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
- Authors: Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, Cardaci G, Gray B
- Issue date: 2004 Nov 1
- Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer.
- Authors: Makower D, Wadler S
- Issue date: 1999 Dec